November 18, 2019 - We believe FX-322 has the potential to be a restorative, disease-modifying treatment for the millions of patients with hearing loss, with the aim of improving hearing function, including speech intelligibility.

March 18, 2021 - Frequency Therapeutics (Woburn, Mass.) recently announced promising data related to its experimental FX-322 drug.

July 12, 2022 - Frequency Therapeutics has treated the first patients in a Phase l/ll clinical trial to investigate the safety of FX-322 for the treatment of patients with sensorineural hearing loss.

February 22, 2021 - Individuals with stable SNHL that received a single dose of FX-322 showed improvements in the number of words recognized in quiet from baseline to day 90 in the WR test (p=0.029) and the level of background noise in which words could be identified in the WIN test (p=0.012).

(RTTNews) - Frequency Therapeutics Inc. (FREQ) said that new results from its FX-322-111 open-label study suggested that the hearing of individuals administered with a single dose of FX-322 may improve over extended periods.FX-322 is Frequency's lead product candidate for the tre

June 12, 2022 - Frequency Therapeutics (FREQ)perks up 5.6% premarket after publishing its FX-322 Phase 1/2 study results in Otology & Neurotology, a peer-reviewed journal focused on disorders of...

October 10, 2019 - The fast-track program aims to speed up the approval of therapies for unmet needs in serious conditions. Woburn, Mass.-based Frequency’s FX-322 candidate is designed to stimulate the regrowth of sensory hair cells to treat chronic noise-induced hearing loss.

July 22, 2019 - The trial assessed the safety of a single dose of FX-322 given by intratympanic administration in patients with stable sensorineural hearing loss (SSHL).

December 27, 2022 - We catch up with Drs. Carl LeBel and Kevin Franck to discuss latest update on Frequency's hearing loss treatments under development: FX-322 and FX-345

Pioneering RNA editing to deliver the future of medicine · RNA editing holds great promise to rewrite what’s possible for patients. Since the discovery of the first generation of editing technologies, researchers have been working to overcome the inherent complexity of these initial approaches ...

FX-322: a Stem cells stimulants Drug, Initially developed by Frequency Therapeutics, Inc., Now, its global highest R&D status is Phase 2, Mechanism: Stem cells stimulants, Therapeutic Areas: Nervous System Diseases,Otorhinolaryngologic Diseases, Active Org.: Frequency Therapeutics, Inc..

We are developing our lead product candidate, FX-322, to treat the underlying cause of SNHL. SNHL is the most prevalent type of hearing loss, typically caused by permanent loss of sensory hair cells in the cochlea within the ear. No drug therapies have been approved by the U.S.

LEXINGTON, Mass. --(BUSINESS WIRE)--Dec. 9, 2021-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today shared the results from its FX-322-113

November 4, 2022 - Frequency Therapeutics, a publicly traded (NASDAQ) company based in Lexington, Massachusetts, has published a series of clinical trials showing early promise that a pharmacologic agent, FX-322, regenerates human hair cells in the cochlea. During this interview with Brian Taylor, Frequency’s ...

November 8, 2022 - The FX-322-208 study is designed to show a statistically significant improvement in speech perception, and its pre-specified endpoint would also demonstrate a clinically meaningful outcome for patients. We believe the pending FX-322 data have the potential to support a future marketing application ...

September 15, 2020 - Frequency Therapeutics presented results from a longer-term durability study of its acquired sensorineural hearing loss candidate, saying FX-322 showed significant improvement for some patients in key measures of hearing that were sustained for up to 21 months.

Twitter

As he says, “specifics around pricing and regulatory ‘really need to be managed and played out appropriately'” (in other words, NOT eagerly telling us “FX-322 WILL COST EXACTLY THESE MANY DOLLARS” while the drug is still in phase 2a clinical trials).

This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural hearing loss (SNHL).